The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Sangeetha Venugopal, MDMyelofibrosis | September 20, 2023
Myelofibrosis Awareness Day is marked on September 20th each year.
View More
Leah LawrenceMeeting News | September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah SherwoodMyelofibrosis | September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Cecilia BrownMyelofibrosis | August 21, 2023
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Cecilia BrownMyelofibrosis | August 21, 2023
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Cecilia BrownMyelofibrosis | August 18, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Cecilia BrownMyelofibrosis | July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Cecilia BrownMyelofibrosis | July 13, 2023
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Cecilia BrownMyeloproliferative Neoplasms | June 20, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Cecilia BrownMyeloproliferative Neoplasms | June 16, 2023
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Cecilia BrownMeeting News | June 15, 2023
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
Keightley AmenMyelofibrosis | June 11, 2023
Spleen volume reduction predicts OS in patients with myelofibrosis who are taking pacritinib.
Keightley AmenMyelofibrosis | June 8, 2023
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
Cecilia BrownMyeloproliferative Neoplasms | June 8, 2023
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
Cecilia BrownMeeting News | June 7, 2023
The median time to achieving the first spleen volume reduction of at least 35% from baseline was 12 weeks.
Prithviraj Bose, MDMyelofibrosis | June 7, 2023
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
Editorial Board